SPECIAL REPORT: PRESCRIPTION DRUG EMISSIONS EXPECTED TO DOUBLE IN NEARLY EVERY STATE
MILLENNIALS, RESIDENTS FROM BIGGEST USPECTIVE MARKET TRYING TO LIMIT THEIR CARBON, CONTINUE TO BE MAINALLY INDEPENDENT
NEW PITY TEST SHOWS TEENS REBOUNDING FROM OPIOID ABUSE
THE DISORDER USUALLY IMPACTS YOUNG PEOPLE
SOURCE: U.S. MENTAL HEALTH ASSOCIATION
And the drugmaker will also soon get permission to market the pills to physicians, according to reports.
“It is pretty disappointing, it was an issue of whether or not it will actually advance the science,” said Senator James Lankford (R-OK).
“We’re going to see plenty of drug sales continue as they have been. This decision has absolutely no negative impact on public health at all, which is a victory for the President,” Lankford said.
The FDA’s decision comes as the agency works on a plan to regulate opioids and other prescription drugs. Administrator Scott Gottlieb stressed the agency’s responsibility to act swiftly and he said Monday’s decision was taken in response to requests from all levels of government.
“This was an opportunity for our agency to review a treatment that is already safe and effective, and determine if it’s appropriate to expand its use,” Gottlieb said.
Bayer has also issued a statement regarding the approval of Acetadote to move forward as a post-operative pain reliever:
“For decades, buprenorphine has been used safely in post-surgical pain settings as a management option for patients in the United States and elsewhere. We remain committed to supporting the continued safe use of buprenorphine in the United States and elsewhere.”
Click HERE for complete details from the New York Times article.